This company has been marked as potentially delisted and may not be actively trading. Dynavax Technologies (DVAX) FDA Approvals Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Dynavax Technologies' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Dynavax Technologies (DVAX). Over the past two years, Dynavax Technologies has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Z-1018. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Z-1018 FDA Regulatory Events Z-1018 is a drug developed by Dynavax Technologies for the following indication: Shingles Vaccine Profile. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Top-line data - October 21,2025Top-Line Data Phase 1/2Drug: Z-1018Announced Date: October 21, 2025Indication: Shingles Vaccine ProfileAnnouncementDynavax Technologies today presented positive topline data from Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, in a late-breaker session at IDWeek 2025.AI SummaryAt IDWeek 2025, Dynavax presented topline results from Part 1 of its Phase 1/2 trial of Z-1018, a new shingles vaccine. In this study, adults aged 50–69 received different doses and formulations of Z-1018 or Shingrix. Four weeks after two doses, Z-1018 produced antibody and CD4+ T-cell responses comparable to Shingrix. Z-1018 also drove robust polyfunctional CD4+ T-cell responses, showing activation markers on multiple cell functions. Across dosing levels and intervals, Z-1018 was well tolerated, with mostly mild local and systemic reactions. The company selected a 100 mcg dose of antigen with CpG 1018 plus alum, given at 0 and 8 weeks, to move forward. Dynavax has now started Part 2, a head-to-head study versus Shingrix in about 324 adults aged 70 and older in Australia and New Zealand. Topline results from Part 2 are expected in late 2026 to confirm Z-1018’s immunogenicity, safety, and tolerability.Read AnnouncementTop-line results - August 21,2025Top-Line Results Phase 1/2Drug: Z-1018Announced Date: August 21, 2025Indication: Shingles Vaccine ProfileAnnouncementDynavax Technologies announced positive topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years.AI SummaryDynavax Technologies announced positive topline results from Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 trial of Z-1018, its novel shingles vaccine candidate, against Shingrix in adults aged 50 to 69. The study evaluated three antigen doses, two adjuvant formulations, and two dosing intervals. One month after the second dose, Z-1018 induced antibody and CD4⁺ T cell responses comparable to Shingrix, with a 100.0% humoral vaccine response rate versus 96.9% for Shingrix, and an 89.7% cellular response rate versus 93.5%. Composite response rates were 89.7% for Z-1018 and 90.3% for Shingrix. Z-1018 was well tolerated, with only 12.5% of participants reporting grade 2 or 3 local reactions and 27.5% reporting systemic reactions, compared to 52.6% and 63.2% for Shingrix, respectively. Based on these results, Dynavax selected the 100 µg glycoprotein E dose adjuvanted with CpG 1018 and alum and an 8-week schedule to advance into Part 2 of the trial in adults 70 and older, expected to begin in the second half of 2025.Read Announcement Dynavax Technologies FDA Events - Frequently Asked Questions Has Dynavax Technologies received FDA approval? As of now, Dynavax Technologies (DVAX) has not received any FDA approvals for its therapy in the last two years. What drugs has Dynavax Technologies submitted to the FDA? In the past two years, Dynavax Technologies (DVAX) has reported FDA regulatory activity for Z-1018. What is the most recent FDA event for Dynavax Technologies? The most recent FDA-related event for Dynavax Technologies occurred on October 21, 2025, involving Z-1018. The update was categorized as "Top-line data," with the company reporting: "Dynavax Technologies today presented positive topline data from Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, in a late-breaker session at IDWeek 2025." What conditions do Dynavax Technologies' current drugs treat? Currently, Dynavax Technologies has one therapy (Z-1018) targeting the following condition: Shingles Vaccine Profile. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Agenus FDA EventsAkari Therapeutics FDA EventsBioCardia FDA EventsBioXcel Therapeutics FDA EventsCogent Biosciences FDA EventsEntera Bio FDA EventsImmunic FDA EventsMiNK Therapeutics FDA EventsZenas BioPharma FDA EventsAltimmune FDA EventsAmarin FDA EventsApogee Therapeutics FDA EventsArrowhead Pharmaceuticals FDA EventsAtossa Genetics FDA EventsAtea Pharmaceuticals FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Alkermes FDA Events Ligand Pharmaceuticals FDA Events Celldex Therapeutics FDA Events BioCryst Pharmaceuticals FDA Events Innoviva FDA Events Novavax FDA Events Zenas BioPharma FDA Events Lexicon Pharmaceuticals FDA Events MannKind FDA Events OPKO Health FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:DVAX last updated on 10/21/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersThe "hidden" half of the SpaceX IPOMost investors are focused on the SpaceX IPO - but the bigger opportunity may lie elsewhere. On Feb. 2, Elon M...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredHow daily 'stock bets' hit 87% of the timeA daily trading system claims an 87% win rate on short-term stock plays - and it runs just one hour a day, fro...Trade To Close | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang may hold the answer to ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Top-line data - October 21,2025Top-Line Data Phase 1/2Drug: Z-1018Announced Date: October 21, 2025Indication: Shingles Vaccine ProfileAnnouncementDynavax Technologies today presented positive topline data from Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, in a late-breaker session at IDWeek 2025.AI SummaryAt IDWeek 2025, Dynavax presented topline results from Part 1 of its Phase 1/2 trial of Z-1018, a new shingles vaccine. In this study, adults aged 50–69 received different doses and formulations of Z-1018 or Shingrix. Four weeks after two doses, Z-1018 produced antibody and CD4+ T-cell responses comparable to Shingrix. Z-1018 also drove robust polyfunctional CD4+ T-cell responses, showing activation markers on multiple cell functions. Across dosing levels and intervals, Z-1018 was well tolerated, with mostly mild local and systemic reactions. The company selected a 100 mcg dose of antigen with CpG 1018 plus alum, given at 0 and 8 weeks, to move forward. Dynavax has now started Part 2, a head-to-head study versus Shingrix in about 324 adults aged 70 and older in Australia and New Zealand. Topline results from Part 2 are expected in late 2026 to confirm Z-1018’s immunogenicity, safety, and tolerability.Read Announcement
Top-line results - August 21,2025Top-Line Results Phase 1/2Drug: Z-1018Announced Date: August 21, 2025Indication: Shingles Vaccine ProfileAnnouncementDynavax Technologies announced positive topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years.AI SummaryDynavax Technologies announced positive topline results from Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 trial of Z-1018, its novel shingles vaccine candidate, against Shingrix in adults aged 50 to 69. The study evaluated three antigen doses, two adjuvant formulations, and two dosing intervals. One month after the second dose, Z-1018 induced antibody and CD4⁺ T cell responses comparable to Shingrix, with a 100.0% humoral vaccine response rate versus 96.9% for Shingrix, and an 89.7% cellular response rate versus 93.5%. Composite response rates were 89.7% for Z-1018 and 90.3% for Shingrix. Z-1018 was well tolerated, with only 12.5% of participants reporting grade 2 or 3 local reactions and 27.5% reporting systemic reactions, compared to 52.6% and 63.2% for Shingrix, respectively. Based on these results, Dynavax selected the 100 µg glycoprotein E dose adjuvanted with CpG 1018 and alum and an 8-week schedule to advance into Part 2 of the trial in adults 70 and older, expected to begin in the second half of 2025.Read Announcement
